Gleason score and docetaxel response in advanced hormone-sensitive prostate cancer: The lower the better

Gleason score and docetaxel response in advanced hormone-sensitive prostate cancer: The lower the better

Aim: Recently, three randomized controlled trials evaluated the addition of docetaxel to ADT in advanced hormone-sensitive prostate cancer (aHSPC). Interestingly, all trials showed a trend towards improved OS in the subgroup of patients with Gleason <8 tumors. We herein performed a meta-analysis...

Full description

Bibliographic Details
Main Authors: Omer Dizdar, Deniz Can Guven, Gurkan Guner, Mustafa Erman, Mutlu Hayran
Format: Article
Language:English
Published: Turkiye Klinikleri 2019-08-01
Series:Journal of Oncological Sciences
Online Access:http://www.sciencedirect.com/science/article/pii/S2452336418300967

Similar Items

Similar Items